Evaluation of serum and tissue levels of VAP-1 in colorectal cancer. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Ward, Stephen; Weston, Christopher; Shepherd, Emma; Hejmadi, Rahul; Ismail, Tariq; Adams, David
• Is Part Of: BMC cancer. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 8
• Publication Date: 2016-12
• Subjects: VAP-1 -- AOC3 -- Colorectal Cancer -- Tumor Markers; Cancer -- Periodicals; 616.994005
• DOI: 10.1186/s12885-016-2183-7
• Languages: English
• ISSNs: 1471-2407

Abstract

Abstract Background The endothelial adhesion molecule, vascular adhesion protein-1 (VAP-1, AOC3 ) promotes lymphocyte recruitment to tumours, although the contribution that VAP-1 makes to lymphocyte recruitment in human colorectal cancer (CRC) is unknown. VAP-1 exists in circulating soluble form (sVAP-1). A previous study demonstrated elevated sVAP-1 levels in CRC patients. The aim of this study was to confirm this finding and study the differences in tissue VAP-1 expression between CRC and healthy tissues. Methods sVAP-1 levels were measured in the serum of 31 patients with CRC and 31 age- and sex-matched controls. Tissue VAP-1 levels were measured by immunohistochemistry, quantitative real-time PCR and Western blotting. Results The mean sVAP-1 level ± SD was significantly lower in the CRC group compared with the control group (399 ± 138 ng/ml versus 510 ± 142 ng/ml, P = 0.003). Tissue VAP-1 protein and mRNA levels were significantly lower in CRC compared with normal colon tissue. VAP-1 immunostaining was practically absent from CRC. Conclusions VAP-1 is downregulated in human CRC and although the molecular basis of this down regulation is not yet known, we suggest it may be part of a mechanism used by the tumour to prevent the recruitment of anti-tumour immune cells. Our data contradicts the findings of others with regard sVAP-1 levels in patients with CRC. Possible reasons for this are discussed.